More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.88B
EPS
-1.42
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
-0.080021
Previous close
$29.50
Today's open
$29.85
Day's range
$28.76 - $30.32
52 week range
$10.83 - $41.14
show more
CEO
Joshua Cohen
Employees
136
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
128562904
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical Officer Dan Monahan - Chief Commercial Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Jacob Ormes - TD Securities Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division Geoffrey Meacham - Citigroup Inc. Exchange Research Marc Goodman - Leerink Partners LLC, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Samuel Lee - Mizuho Securities USA LLC, Research Division Dina Ramadane - BofA Securities, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Christopher Chen - Robert W.
Seeking Alpha • Nov 6, 2026

Amylyx Pharmaceuticals Q3 Earnings Call Highlights
Amylyx Pharmaceuticals NASDAQ: AMLX plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027 following positive late-stage trial results.
MarketBeat • Nov 5, 2026

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.
Business Wire • Nov 5, 2026

Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.
Business Wire • Nov 4, 2026

Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.
Business Wire • Nov 3, 2026

Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.
Business Wire • Nov 2, 2026

11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
Schaeffers Research • Oct 12, 2026

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
Business Wire • Oct 6, 2026

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
MarketBeat • Oct 3, 2026

10 Stocks With Massive Short Squeeze Potential
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
Schaeffers Research • Oct 1, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Amylyx Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.